EFFICACY AND SAFETY OF VARIOUS DOSES OF RITUXIMAB IN RHEUMATOID ARTHRITIS (RA) PATIENTS: A SYSTEMATIC APPROACH TO RANDOMIZED CLINICAL TRIALS
Sanjo Saijan, Joicy Jose*, Aby Paul, Swetha Jos and Jobin Kunjumon Vilapurathu
ABSTRACT
Rituximab being a cytolytic monoclonal antibody is used to various disease including Non- Hodgkin’s Lymphoma, Chronic lymphocytic Leukemia, Wegener’s granulomatosis, microscopic polyangiitis and in combination with methotrexate for rheumatoid arthritis who failed TNF antagonist therapy.[1] Based on the clinical evidence the dose of Rituximab for Rheumatoid arthritis varies. The dose which shows the maximum efficacy in RA is still a challenging task for the physicians. This is a narrative review which emphasis on the efficacy and safety of various doses of Rituximab in RA patients.
Keywords: Chronic lymphocytic Leukemia, Wegener’s granulomatosis.
[Full Text Article]
[Download Certificate]